Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Urinary Bladder Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2Triple Negative Breast Neoplasms 2Carcinoma, Transitional Cell 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

X-Rays 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Phantoms, Imaging 6Biopsy 5Nuclear Medicine Department, Hospital 4Methotrexate 4Doxorubicin 4cixutumumab 3cabozantinib 3Temozolomide 3Leucovorin 3Filgrastim 3Cyclophosphamide 3Cisplatin 3ulixertinib 2tipifarnib 2temsirolimus 2tazemetostat 2tanespimycin 2selpercatinib 2palbociclib 2olaparib 2merphos 2larotrectinib 2ixabepilone 2ivosidenib 2ensartinib 2dinutuximab 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Osteosarcoma × eribulin × Clear all
NCT02097238 2020-05-19

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 12 charts
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡